BiotechTube
Hillstar Bio

Hillstar Bio

San Diego, United States· Est.
hillstarbio.com
Is this your company? Claim your profile to update info and connect with investors.
Claim profile

Private Company

Total funding raised: $72M

Overview

Hillstar Bio is a private, preclinical-stage biotech developing targeted immunotherapies designed to deplete disease-causing immune cells in autoimmune conditions. Its lead program, HSB-101, targets TRBV9+ T cells for axial spondyloarthritis (AxSpA) and is anticipated to enter Phase 1 trials in 2026. The company is backed by prominent venture capital firms and leverages a strategy of antibody engineering against validated genetic markers to de-risk development and move beyond the chronic, broad immunosuppression of current standard-of-care treatments.

Autoimmune DiseasesImmunology

Technology Platform

Precision antibody engineering for selective depletion of pathogenic immune cells based on disease-specific genetic markers (e.g., TRBV9).

Funding History

2
Total raised:$72M
Series A$67M
Seed$5M

Opportunities

The large and growing autoimmune disease market, particularly axial spondyloarthritis, presents a significant opportunity for a therapy that offers durable remission with less frequent dosing.
The precision, biomarker-driven approach aligns with trends in personalized medicine and could enable faster clinical development and targeted commercialization.
Success in AxSpA could allow expansion into other HLA-B27-associated inflammatory conditions.

Risk Factors

High scientific risk that the targeted depletion of specific T-cell subsets will prove safe and effective in humans.
Intense competition from established and novel autoimmune therapies.
Execution risk in advancing to clinical trials on schedule and securing necessary future financing.

Competitive Landscape

Hillstar operates in the competitive autoimmune biologics space, dominated by large pharma companies with TNF and IL-17/23 inhibitors. It differentiates through precision depletion aiming for an 'immune reset,' competing against other next-generation modalities like CAR-Tregs, bispecifics, and targeted kinase inhibitors. Its initial focus on a specific AxSpA subpopulation may offer a niche entry point.

More companies in United States →